<DOC>
	<DOCNO>NCT00732771</DOCNO>
	<brief_summary>The purpose study determine LCI699 , thorough reduction aldosterone , low BP patient Primary hyperaldosteronism .</brief_summary>
	<brief_title>Proof-of-concept Aldosterone Synthase Inhibitor LCI699 Patients With Primary Hyperaldosteronism</brief_title>
	<detailed_description />
	<mesh_term>Hyperaldosteronism</mesh_term>
	<criteria>Diagnosis primary hyperaldosteronism ( PH ) within last 3 year , either without aldosterone produce adenoma ( APA ) . Hypertension screen Persistent hypokalemia Renal impairment Significant hepatic disease Any surgical medical condition may significantly alter absorption , distribution , metabolism excretion drug substance Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>primary hyperaldosteronism</keyword>
	<keyword>hypokalemia</keyword>
	<keyword>hypertension</keyword>
	<keyword>aldosterone synthase inhibitor</keyword>
</DOC>